On March 6, a specialized panel of Japan’s Ministry of Health, Labor and Welfare approved adding “sleep disorders” to the list of medical department names that medical institutions can display on signboards and in advertisements. It is the first addition since 2008.
An advisory panel to Japan’s health minister decided Friday to allow public health insurance coverage for a gene therapy for muscular dystrophy beginning Feb. 20 and set the drug’s official price at about 304.97 million yen. Elevidys, a one-time treatment for Duchenne muscular dystrophy in ambulatory patients aged 3-7, will become the country’s most expensive drug.
An advisory panel to Japan’s health minister decided Friday to allow public health insurance coverage for a gene therapy for muscular dystrophy beginning Feb. 20 and set the drug’s official price at about 304.97 million yen. Elevidys, a one-time treatment for Duchenne muscular dystrophy in ambulatory patients aged 3-7, will become the country’s most expensive drug.
A Tokyo man in his 50s who was forced to quit his IT job after developing Parkinson’s disease faced difficulties obtaining Japan’s disability pension due to the system’s requirement to prove the date of first medical consultation, highlighting structural hurdles for applicants. Kenichi Sato (pseudonym), 54, was told he needed to verify an initial clinic visit from about 20 years ago, but records had been discarded under the legal five-year retention rule for medical charts.
The online survey was conducted by the Nippon Foundation last October targeting 2,500 family members of people with disabilities. Overall, 36.2% said they were “very anxious” about the future, 27.6% “anxious,” and 21.7% “slightly anxious.”
Japan’s health ministry will designate eight drug ingredients as having abuse potential under law in response to rising concerns about the overdose of over-the-counter drugs among young people, it has been learned. The ministry will publicly notify the decision, made by its subcommittee on Friday, in mid-February. Currently, six ingredients commonly found in cold or cough medicines are designated as drugs that may be abused under ministerial ordinances and other rules. The new designation will add dextromethorphan, an antitussive ingredient, and diphenhydramine, an antihistamine, bringing the total number of designated substances to eight.
Japan’s Ministry of Health, Labour and Welfare will hold a meeting on Thursday, Jan. 29, to examine disease names covered by certification criteria for mental disorders following the domestic application of the ICD-11 international disease classification system. The study group, convened under the supervision of the ministry’s Director-General for Policy Planning in charge of industrial accidents and wages, is composed of experts with specialized knowledge in medicine and related fields. Members of the public wishing to observe the meeting must apply in advance in accordance with the ministry’s observer guidelines.
Taro Yamamoto, leader of Japanese opposition party Reiwa Shinsengumi, on Wednesday resigned from the House of Councillors, the upper chamber of the Diet, the country’s parliament, due to health problems.
“I’m one step away from multiple myeloma, a cancer of the blood. If I don’t live by the main theme of not letting it progress, I could lose my life,” Yamamoto said in a video posted on the party’s official YouTube channel.
The number of new influenza patients in Japan remained above the warning level of 30 per medical institution last week, the health ministry said Friday. New flu cases reported by 3,000 regularly monitored hospitals and clinics across the country stood at 32.73 on average in the week through Sunday.
Japan’s ruling parties agreed Friday to seek to reduce the country’s medical costs by 188 billion yen per year, by revising the eligibility of certain drugs for insurance coverage. The agreement was struck between the policy chiefs of the Liberal Democratic Party and the Japan Innovation Party (Nippon Ishin no Kai). The government plans to hammer out the details of the revised medical insurance system for pharmaceuticals based on the two parties’ agreement for implementation in the fiscal year beginning next April.
Barrier Free Japan